ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

YTEN Yield10 Bioscience Inc (QB)

0.50
-0.025 (-4.76%)
22 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Yield10 Bioscience Inc (QB) USOTC:YTEN OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -4.76% 0.50 0.3014 0.65 0.50 0.49 0.49 619 21:00:00

Form 8-K - Current report

23/07/2024 9:04pm

Edgar (US Regulatory)


0001121702FALSE00011217022024-07-232024-07-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 
Date of Report (Date of earliest event reported) July 23, 2024
 
YIELD10 BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
 

Delaware001-3313304-3158289
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
19 Presidential Way, Woburn, Massachusetts
 01801
(Address of principal executive offices)(Zip Code)
 
Registrant’s Telephone Number, Including Area Code: (617) 583-1700 
N/A 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o





Item 1.02 Termination of a Material Definitive Agreement.
On July 23, 2024, Yield10 Bioscience, Inc. (the “Company”) and MPC Investment LLC (“MPC”) mutually agreed to terminate a senior unsecured convertible note issued by the Company to MPC on April 28, 2023 (“Convertible Note”) in the original principal amount of $1,000,000, pursuant to a Securities Purchase Agreement (“SPA”). The Convertible Note accrued interest at a rate of 8.0% per annum and had been subject to conversion into shares of the Company’s common stock at a conversion price of $73.68 per share. If not converted to the Company’s common stock, the Convertible Note would have matured on August 24, 2024.
As of the termination date, the Company’s current obligation under the terms of the Convertible Note for principal and unpaid interest totaled $1,100,572. The Company and MPC agreed to a one-time payment of $500,000 in full satisfaction of the Convertible Note principal and unpaid interest. The Company subsequently issued the $500,000 payment to MPC and the Convertible Note and SPA have been fully discharged.
The foregoing descriptions of the Convertible Note and SPA are not complete and are qualified in their entirety by reference to the full text of the Convertible Note and SPA, copies of which were filed as Exhibit 4.1 and Exhibit 10.1, respectively, to the Company’s Current Report on Form 8-K (File No. 001-33133) filed with the Securities and Exchange Commission on May 1, 2023 and incorporated herein by reference.



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  YIELD10 BIOSCIENCE, INC.
   
July 23, 2024By:/s/ Oliver P. Peoples
  Oliver P. Peoples
  President & Chief Executive Officer


v3.24.2
Cover
Jul. 23, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 23, 2024
Entity Registrant Name YIELD10 BIOSCIENCE, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-33133
Entity Tax Identification Number 04-3158289
Entity Address, Address Line One 19 Presidential Way
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code 617
Local Phone Number 583-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Central Index Key 0001121702
Amendment Flag false
Entity Emerging Growth Company false

1 Year Yield10 Bioscience (QB) Chart

1 Year Yield10 Bioscience (QB) Chart

1 Month Yield10 Bioscience (QB) Chart

1 Month Yield10 Bioscience (QB) Chart

Your Recent History

Delayed Upgrade Clock